Roy S. Herbst, MD, PhD, on Lung Cancer With Immune Checkpoints: Promising Combinations

2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Tweet this page

Roy S. Herbst, MD, PhD, of the Yale Cancer Center, discusses immunotherapy as a standard of care in lung cancer, critical biomarkers, and scientifically guided combination treatment, which will be the future of lung cancer immunotherapy.

Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.